NO2768984T3 - - Google Patents
Info
- Publication number
- NO2768984T3 NO2768984T3 NO12841612A NO12841612A NO2768984T3 NO 2768984 T3 NO2768984 T3 NO 2768984T3 NO 12841612 A NO12841612 A NO 12841612A NO 12841612 A NO12841612 A NO 12841612A NO 2768984 T3 NO2768984 T3 NO 2768984T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Organic Insulating Materials (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562254375P | 2015-11-12 | 2015-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2768984T3 true NO2768984T3 (cs) | 2018-06-09 |
Family
ID=57348648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO12841612A NO2768984T3 (cs) | 2015-11-12 | 2012-10-19 |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US10544211B2 (cs) |
| EP (2) | EP3266798A3 (cs) |
| JP (2) | JP6962915B2 (cs) |
| KR (2) | KR102641194B1 (cs) |
| CN (1) | CN108473563B (cs) |
| AU (2) | AU2016352943B2 (cs) |
| BR (1) | BR112018009714A8 (cs) |
| CA (2) | CA3005085C (cs) |
| CL (1) | CL2018001291A1 (cs) |
| CO (1) | CO2018005915A2 (cs) |
| CR (1) | CR20180311A (cs) |
| CY (1) | CY1120303T1 (cs) |
| DK (1) | DK3191511T3 (cs) |
| DO (1) | DOP2018000122A (cs) |
| EC (1) | ECSP18042569A (cs) |
| ES (1) | ES2662418T3 (cs) |
| GT (1) | GT201800095A (cs) |
| HK (1) | HK1248716A1 (cs) |
| HR (1) | HRP20171949T1 (cs) |
| HU (1) | HUE035805T2 (cs) |
| IL (2) | IL259269B2 (cs) |
| LT (1) | LT3191511T (cs) |
| MA (1) | MA41653A (cs) |
| MD (1) | MD3191511T2 (cs) |
| ME (1) | ME02954B (cs) |
| MX (1) | MX385207B (cs) |
| NO (1) | NO2768984T3 (cs) |
| PE (1) | PE20181317A1 (cs) |
| PH (1) | PH12018501025A1 (cs) |
| PL (1) | PL3191511T3 (cs) |
| PT (1) | PT3191511T (cs) |
| RS (1) | RS56676B1 (cs) |
| SG (1) | SG11201803975SA (cs) |
| SI (1) | SI3191511T1 (cs) |
| SM (1) | SMT201700590T1 (cs) |
| TN (1) | TN2018000159A1 (cs) |
| WO (1) | WO2017081320A1 (cs) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| ES2622006T5 (es) | 2011-06-23 | 2022-10-13 | Ablynx Nv | Técnicas para predecir, detectar y reducir la interferencia proteica no específica en ensayos que implican dominios variables individuales de inmunoglobulina |
| EP3143042B1 (en) | 2014-05-16 | 2020-06-10 | Ablynx N.V. | Immunoglobulin variable domains |
| NO2768984T3 (cs) * | 2015-11-12 | 2018-06-09 | ||
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| JP7719775B2 (ja) | 2019-12-06 | 2025-08-06 | アブリンクス エン．ヴェー． | ＴＮＦαおよびＯＸ４０Ｌを標的とする免疫グロブリン単一可変ドメインを含むポリペプチド |
| CA3163877A1 (en) * | 2019-12-06 | 2021-06-10 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting tnf.alpha. and il-23 |
| CN112300289B (zh) * | 2019-12-30 | 2022-06-10 | 中国药科大学 | RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用 |
| JP2023553694A (ja) | 2020-12-18 | 2023-12-25 | アブリンクス エン．ヴェー． | ＩＬ－６およびＴＮＦ－αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド |
| EP4435002A4 (en) * | 2021-11-29 | 2025-03-26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | MODIFIED PROTEIN OR POLYPEPTIDE |
| AU2023373192A1 (en) * | 2022-11-04 | 2025-04-17 | St. Jude Children's Research Hospital, Inc. | Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases |
| US20240415974A1 (en) | 2022-12-23 | 2024-12-19 | Ablynx N.V. | Protein-based conjugation carriers |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0656946T4 (da) | 1992-08-21 | 2010-07-26 | Univ Bruxelles | Immunoglobuliner uden lette kæder |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| WO1999023221A2 (en) | 1997-10-27 | 1999-05-14 | Unilever Plc | Multivalent antigen-binding proteins |
| HK1041210A1 (zh) | 1998-02-19 | 2002-07-05 | 埃克斯西特治疗公司 | 用於调节淋巴细胞活化的组合物及方法 |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| CA2505326A1 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
| NZ540771A (en) | 2003-01-10 | 2009-05-31 | Ablynx Nv | Recombinant VHH single domain antibody from camelidae against von willebrand factor (vWF) or against collagen |
| CN1845938B (zh) | 2003-06-30 | 2010-05-26 | 杜门蒂斯有限公司 | 多肽 |
| EP2251357A1 (en) | 2003-11-07 | 2010-11-17 | Ablynx N.V. | Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor |
| KR20070084170A (ko) | 2004-10-13 | 2007-08-24 | 아블린쓰 엔.브이. | 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드 |
| CN101133084A (zh) | 2004-12-02 | 2008-02-27 | 多曼蒂斯有限公司 | 采用白细胞介素-1ⅰ型受体拮抗剂治疗呼吸道疾病的方法 |
| HUE045710T2 (hu) | 2005-05-18 | 2020-01-28 | Ablynx Nv | Javított, alfa tumor nekrózis faktor elleni nanobodies |
| US7807162B2 (en) | 2005-05-20 | 2010-10-05 | Ablynx N.V. | Single domain VHH antibodies against von Willebrand factor |
| DE102005023617A1 (de) * | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| AU2006286563B2 (en) | 2005-08-30 | 2012-02-23 | Intrexon Actobiotics Nv | Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis |
| TW200736276A (en) | 2005-12-01 | 2007-10-01 | Domantis Ltd | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| TW200730539A (en) | 2005-12-01 | 2007-08-16 | Domantis Ltd | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| US20100047171A1 (en) | 2006-01-24 | 2010-02-25 | Roland Beckmann | Fusion Proteins That Contain Natural Junctions |
| CA2666599A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| AU2007328900A1 (en) | 2006-12-05 | 2008-06-12 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| WO2012130874A1 (en) | 2011-03-28 | 2012-10-04 | Ablynx Nv | Bispecific anti-cxcr7 immunoglobulin single variable domains |
| US8623361B2 (en) | 2007-05-24 | 2014-01-07 | Ablynx N.V. | Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders |
| AU2008328781A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| BRPI0911984A2 (pt) | 2008-05-16 | 2016-09-20 | Ablynx Nv | sequências de aminoácidos direncionadas contra cxcr4 e outros compostos gpcrs compreendendo os mesmos |
| EP2398827A2 (en) * | 2009-02-19 | 2011-12-28 | Glaxo Group Limited | Improved anti-tnfr1 polypeptides, antibody variable domains&antagonists |
| SG174862A1 (en) | 2009-04-10 | 2011-11-28 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| SG177601A1 (en) | 2009-07-16 | 2012-02-28 | Glaxo Group Ltd | Improved anti-serum albumin binding single variable domains |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| PL2723771T3 (pl) | 2011-06-23 | 2020-04-30 | Ablynx Nv | Białka wiążące albuminy surowicy |
| ES2622006T5 (es) * | 2011-06-23 | 2022-10-13 | Ablynx Nv | Técnicas para predecir, detectar y reducir la interferencia proteica no específica en ensayos que implican dominios variables individuales de inmunoglobulina |
| SG10201605891TA (en) * | 2011-08-17 | 2016-09-29 | Glaxo Group Ltd | Modified proteins and peptides |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| EP3143042B1 (en) * | 2014-05-16 | 2020-06-10 | Ablynx N.V. | Immunoglobulin variable domains |
| NO2768984T3 (cs) * | 2015-11-12 | 2018-06-09 | ||
| AU2017216864B2 (en) * | 2016-02-12 | 2023-06-22 | Ablynx Nv | Method for the production of immunoglobulin single variable domains |
-
2012
- 2012-10-19 NO NO12841612A patent/NO2768984T3/no unknown
-
2016
- 2016-11-13 MA MA041653A patent/MA41653A/fr unknown
- 2016-11-14 PE PE2018000766A patent/PE20181317A1/es unknown
- 2016-11-14 DK DK16798122.4T patent/DK3191511T3/en active
- 2016-11-14 CR CR20180311A patent/CR20180311A/es unknown
- 2016-11-14 US US15/501,011 patent/US10544211B2/en active Active
- 2016-11-14 EP EP17184686.8A patent/EP3266798A3/en not_active Withdrawn
- 2016-11-14 SG SG11201803975SA patent/SG11201803975SA/en unknown
- 2016-11-14 ES ES16798122.4T patent/ES2662418T3/es active Active
- 2016-11-14 SI SI201630013T patent/SI3191511T1/en unknown
- 2016-11-14 IL IL259269A patent/IL259269B2/en unknown
- 2016-11-14 KR KR1020187016731A patent/KR102641194B1/ko active Active
- 2016-11-14 CN CN201680076588.6A patent/CN108473563B/zh active Active
- 2016-11-14 LT LTEP16798122.4T patent/LT3191511T/lt unknown
- 2016-11-14 MX MX2018005992A patent/MX385207B/es unknown
- 2016-11-14 CA CA3005085A patent/CA3005085C/en active Active
- 2016-11-14 PT PT167981224T patent/PT3191511T/pt unknown
- 2016-11-14 WO PCT/EP2016/077595 patent/WO2017081320A1/en not_active Ceased
- 2016-11-14 KR KR1020247005963A patent/KR20240029115A/ko active Pending
- 2016-11-14 EP EP16798122.4A patent/EP3191511B1/en active Active
- 2016-11-14 TN TNP/2018/000159A patent/TN2018000159A1/en unknown
- 2016-11-14 AU AU2016352943A patent/AU2016352943B2/en active Active
- 2016-11-14 ME MEP-2017-291A patent/ME02954B/me unknown
- 2016-11-14 JP JP2018524836A patent/JP6962915B2/ja active Active
- 2016-11-14 MD MDE20170066T patent/MD3191511T2/ro unknown
- 2016-11-14 CA CA3234178A patent/CA3234178A1/en active Pending
- 2016-11-14 IL IL310373A patent/IL310373A/en unknown
- 2016-11-14 HR HRP20171949TT patent/HRP20171949T1/hr unknown
- 2016-11-14 PL PL16798122T patent/PL3191511T3/pl unknown
- 2016-11-14 BR BR112018009714A patent/BR112018009714A8/pt active Search and Examination
- 2016-11-14 SM SM20170590T patent/SMT201700590T1/it unknown
- 2016-11-14 HU HUE16798122A patent/HUE035805T2/en unknown
- 2016-11-14 RS RS20171299A patent/RS56676B1/sr unknown
-
2017
- 2017-03-13 US US15/456,824 patent/US9745372B2/en active Active
- 2017-12-01 HK HK18108106.4A patent/HK1248716A1/en unknown
- 2017-12-19 CY CY20171101330T patent/CY1120303T1/el unknown
-
2018
- 2018-05-11 GT GT201800095A patent/GT201800095A/es unknown
- 2018-05-11 CL CL2018001291A patent/CL2018001291A1/es unknown
- 2018-05-11 DO DO2018000122A patent/DOP2018000122A/es unknown
- 2018-05-15 PH PH12018501025A patent/PH12018501025A1/en unknown
- 2018-06-05 EC ECIEPI201842569A patent/ECSP18042569A/es unknown
- 2018-06-08 CO CONC2018/0005915A patent/CO2018005915A2/es unknown
-
2021
- 2021-10-14 JP JP2021168871A patent/JP7357038B2/ja active Active
-
2023
- 2023-01-10 AU AU2023200113A patent/AU2023200113A1/en active Pending